Last reviewed · How we verify

Levobupivacaine bolus analgesia

Osijek University Hospital · FDA-approved active Small molecule Quality 5/100

Levobupivacaine bolus analgesia is a Small molecule drug developed by Osijek University Hospital. It is currently FDA-approved. Also known as: Postoperative wound infiltration with bolus applications of local anesthetic, Chirocaine 0.5%.

At a glance

Generic nameLevobupivacaine bolus analgesia
Also known asPostoperative wound infiltration with bolus applications of local anesthetic, Chirocaine 0.5%
SponsorOsijek University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Levobupivacaine bolus analgesia

What is Levobupivacaine bolus analgesia?

Levobupivacaine bolus analgesia is a Small molecule drug developed by Osijek University Hospital.

Who makes Levobupivacaine bolus analgesia?

Levobupivacaine bolus analgesia is developed and marketed by Osijek University Hospital (see full Osijek University Hospital pipeline at /company/osijek-university-hospital).

Is Levobupivacaine bolus analgesia also known as anything else?

Levobupivacaine bolus analgesia is also known as Postoperative wound infiltration with bolus applications of local anesthetic, Chirocaine 0.5%.

What development phase is Levobupivacaine bolus analgesia in?

Levobupivacaine bolus analgesia is FDA-approved (marketed).

Related